E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.
Frisch
Steven M
SM
The Burnham Institute, La Jolla, California 92037, USA. sfrisch@burnham.org
D017500:Adenovirus E1A Proteins / Q000235:genetics / Q000502:physiology*; D024201:Bystander Effect; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007274:Injections, Intraperitoneal; D008055:Lipids / Q000737:chemistry; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D009687:Nuclear Proteins / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000628:therapy; D010957:Plasmids / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D016160:Retinoblastoma Protein / Q000378:metabolism; D015534:Trans-Activators / Q000378:metabolism
D017500:Adenovirus E1A Proteins; D008055:Lipids; D009687:Nuclear Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016160:Retinoblastoma Protein; D015534:Trans-Activators